about
The vulvovaginal gingival syndrome: a severe subgroup of lichen planus with characteristic clinical features and a novel association with the class II HLA DQB1*0201 allele.World Workshop on Oral Medicine VI: a systematic review of the treatment of mucocutaneous pemphigus vulgaris.World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid.U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016.Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: Clinicopathologic findings in a cohort of 10 patients.Return of the Great Pox.How to do conjunctival and buccal biopsies to investigate cicatrising conjunctivitis: improving the diagnosis of ocular mucous membrane pemphigoid.Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease.Serum and salivary IgG and IgA antibodies to desmoglein 3 in mucosal pemphigus vulgaris.Salivary IgA and IgG antibodies to bullous pemphigoid 180 noncollagenous domain 16a as diagnostic biomarkers in mucous membrane pemphigoid.Mucous Membrane Pemphigoid with Ocular Involvement: The Clinical Phenotype and Its Relationship to Direct Immunofluorescence Findings.An Oral Disease Severity Score (ODSS) validated for use in oral pemphigus vulgaris.British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017.Genetic analysis of desmoglein 3 (DSG3) sequence variants in patients with pemphigus vulgarisEvidence of an association between desmoglein 3 haplotypes and pemphigus vulgarisLacrimal canalicular duct scarring in patients with lichen planusGenome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02Oral and genital lichenoid reactions associated with circulating autoantibodies to desmoplakins I and II: a novel target antigen or example of epitope spreading?Generalised granuloma annulare successfully treated with PUVAClinicopathological case 1: mucous membrane pemphigoid, epidermolysis bullosa acquisita and linear immunoglobulin A diseaseComa-induced bullae and sweat gland necrosis following clobazamMycosis fungoides involving the oral mucosa in a childMucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG productionA case of vulvovaginal gingival lichen planus in association with Good's syndromeA scoring system for mucosal disease severity with special reference to oral lichen planusA swollen lipBullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severityErythema elevatum diutinum with oral ulcerationRecurrent acute bilateral facial pain and swelling in a patient with severe recalcitrant pemphigus vulgarisHLA alleles in British Caucasians with mucous membrane pemphigoidUK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016 (print summary - Full guidelines available at http://dx.doi.org/10.1016/j.bjps.2016.01.034)The optimal oral biopsy site for diagnosis of mucous membrane pemphigoid and pemphigus vulgarisValidation of an Oral Disease Severity Score (ODSS) tool for use in oral mucous membrane pemphigoidA painful vegetating fingerMucous membrane pemphigoid and oral blistering diseasesWorld Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic reviewRituximab with prednisolone as first-line treatment in pemphigus vulgaris
P50
Q36509696-B892229A-8A43-42AE-97B4-130691FFE4ACQ38454444-F3189C24-1B52-4F3C-A8EF-A479B26D5042Q38466390-5BE111D5-FB9F-4CAF-A1B5-40702F08437EQ38851480-744B5C22-7606-42C5-868C-1CDA45FB8203Q39174357-CE8428DC-7860-4813-9D2F-12129F05EABAQ40606107-DE0EFEEB-3B87-4A74-9CAC-B9B7651C9CE5Q46481342-EFA22EFD-F638-4B54-9062-4FB02AFF314CQ47926970-5950DB16-D92E-412C-AD8C-3DA0F990DE4CQ48256118-0E0BB4C1-4FBB-438D-A1F4-45ECB427865AQ48279461-829D5B21-07AB-4A3B-AE82-6A0AC9AA3847Q48541204-B27DD37F-631A-4BE0-8214-ABAC98C1B6C9Q49344136-1926F18F-BF86-4EA3-9D73-961A01988FC1Q49382688-E37A8BD8-18BB-43B7-8778-DFB490091BA7Q57148915-88E6B10E-FF74-4652-A95B-233762A02A72Q57149110-97BC7DE1-BD67-4F5C-91F3-67F39012DC38Q57644141-E194CAAF-D49A-469E-AB58-C156B3F11AE4Q63433248-3891105E-C613-4504-9945-B3234FDFBE5CQ73129110-4D630BB0-A3A9-4B17-A991-FA298E5C1B82Q73293778-05C947B3-DF0F-4ADC-8788-9706239B8FABQ73566885-9C2AC7B4-7080-417B-8B95-C8DE325F2AF6Q73872901-ECA76AF7-5D15-4CA9-AE05-61C86E69593EQ73888372-1EA17252-06E5-46D8-A845-70CA3E0BF6C4Q74451348-ED742B06-E63B-4C95-9954-01F38A9F7165Q80721788-2030B288-9C2D-4AB1-9995-7272FAD586C2Q80824325-B163ED38-7C45-4873-B482-0E65EB0D234BQ81534152-9BC29305-F803-4290-9530-11CF5F701D4BQ82220531-9F1C2A7B-37B6-4646-8B57-9DA3B3E4E238Q83341764-DB52D968-6CB0-4342-AD6B-591B9422549DQ84081130-1D7952B6-5717-4132-950F-6AFB48067852Q88618989-5E85A72B-46D5-4D9D-B0D6-4B0C2BCD81D5Q89268797-9F96A1F8-868B-47D0-9C62-4035B0A604DDQ90300423-3F553149-3984-493C-B0F1-9C95F4DA69E6Q90393149-E99F8879-90D6-4946-80BD-6B4CEA364521Q91839325-E0842034-D12F-45D3-9E9E-3A027A172B48Q92128714-ADB074BE-D4D3-40E7-A0CA-48336C0C8DD3Q92368680-87036D64-EAE9-4160-9075-3C4DDCFCEE95Q92762292-29B5175D-F28E-45AC-95D1-D1B14EEA0A01
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jane Setterfield
@ast
Jane Setterfield
@de
Jane Setterfield
@en
Jane Setterfield
@es
Jane Setterfield
@fr
Jane Setterfield
@it
Jane Setterfield
@nl
type
label
Jane Setterfield
@ast
Jane Setterfield
@de
Jane Setterfield
@en
Jane Setterfield
@es
Jane Setterfield
@fr
Jane Setterfield
@it
Jane Setterfield
@nl
prefLabel
Jane Setterfield
@ast
Jane Setterfield
@de
Jane Setterfield
@en
Jane Setterfield
@es
Jane Setterfield
@fr
Jane Setterfield
@it
Jane Setterfield
@nl
P106
P1153
56380299300
P31
P496
0000-0002-6056-3273